Article Text

Download PDFPDF
Lowering the bleeding risk in intra-arterial thrombolysis without losing efficiency by excluding adjunctive heparin?
  1. Paul Trouillas
  1. Correspondence to:
 Dr P Trouillas
 Service d’Urgences Neurovasculaires (Stroke Unit), Hôpital Neurologique et Neurochirurgical P. Wertheimer, 59, boulevard Pinel, 69003 Lyon, France

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Lowering the bleeding risk in intra-arterial thrombolysis without losing efficiency by excluding adjunctive heparin

Symptomatic intracerebral haemorrhage (sICH) is the main complication of intravenous (IVT) and intra-arterial thrombolysis (IAT). Factors of grave bleedings after thrombolysis have been recently reviewed.1 Immediate adjunctive heparin is classic in IAT. High doses of heparin may be suspected as a factor of bleeding in IAT on the basis of the Pro-Urokinase (r-proUK) for Acute Cerebral Thromboembolism (PROACT) I study, in which a higher sICH rate (27.3%) was observed in the high-heparin-dose subgroup, when compared with the low-heparin subgroup (6.7%). Even with the lower heparin regimen, the PROACT II study resulted in a sICH rate of …

View Full Text

Footnotes

  • Competing interests: None declared.

Linked Articles